Snapshot from Jun 26, 2026 at 07:00 UTC. For live data and tracking: View Live
Entities / Mapp Biopharmaceutical / Regeneron Pharmaceuticals

Mapp Biopharmaceutical & Regeneron Pharmaceuticals

1 shared events · Importance 3 · Last updated May 30, 2026

Importance
3
Shared Events
1
Actions
0
Sentiment
0
Live sentiment trends, interaction importance charts, and action volume tracking available on the Ergen Dashboard
Shared Events (1)
27
Accidents
Unknown Event
Mapp Biopharmaceutical: Mapp Biopharmaceutical>>>'s pan-ebolavirus antibody drug, MBP134, is a potential candidate for clinical trials against the Uganda — Bundibugyo strain, with development backed by BARDA.
Regeneron Pharmaceuticals: Regeneron Pharmaceuticals has an antibody treatment, a component of Inmazeb, which was approved for the Ebola virus and is being prioritized for clinical trials against the Bundibugyo ebolavirus.
May 18, 2026 · 505 articles
NEWSDESK
Explore this relationship live

Track how Mapp Biopharmaceutical and Regeneron Pharmaceuticals interact across events, view sentiment trends, and discover connected entities.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.